Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Sector Healthcare RiskRating. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). See what's happening in the market right now with MarketBeat's real-time news feed. Latest Share Price and Events. Latest Share Price and Events. The company’s shares closed last Friday at $10.82. Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates, Flexion Therapeutics EPS misses by $0.07, misses on revenue, Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights, Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020, Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 © 2020 Verizon Media. 10/13: FLEXION THERAPEUTICS: Announces Preliminary … Research Reports. Share your opinion and gain insight from other stock traders and investors. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) YAHOO!News 3 days ago Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case Get the latest Flexion Therapeutics, Inc. (FLXN) stock news and headlines to help you in your trading and investment decisions. Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% … Adventurous. Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 42.1% and on October 30th it … BURLINGTON, Mass. Researching Flexion Therapeutics (NASDAQ:FLXN) stock? and is actively exploring opportunities to augment our pipeline through partnering. Company's 52-week low was at $5.01 Flexion Therapeutics sees Q2 Zilretta sales of $15.4M, Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Flexion Therapeutics (NASDAQ:FLXN) Stock Rating Reaffirmed by HC Wainwright, Flexion Therapeutics (NASDAQ:FLXN) Rating Lowered to Hold at Zacks Investment Research, Zacks Investment Research Downgrades Flexion Therapeutics (NASDAQ:FLXN) to Sell, Flexion Therapeutics (NASDAQ:FLXN) Downgraded to Sell at BidaskClub, Flexion Therapeutics (NASDAQ:FLXN) Earns Neutral Rating from Analysts at Goldman Sachs Group, Aging of America is a Catalyst for Flexion Therapeutics (FLXN), Flexion Therapeutics (NASDAQ:FLXN) Trading 6.1% Higher, Flexion Therapeutics' (FLXN) Buy Rating Reiterated at HC Wainwright, HC Wainwright Reaffirms "Buy" Rating for Flexion Therapeutics (NASDAQ:FLXN), Critical Comparison: Flexion Therapeutics (NASDAQ:FLXN) and Dicerna Pharmaceuticals (NASDAQ:DRNA), Earnings Update: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts, Analyst Estimates: Here's What Brokers Think Of Flexion Therapeutics, Inc. (NASDAQ:FLXN) After Its Third-Quarter Report, Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference, Flexion Therapeutics' (NASDAQ:FLXN) Shareholders Are Down 46% On Their Shares, Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates, Flexion Therapeutics EPS beats by $0.01, beats on revenue, Flexion Therapeutics: Q3 Earnings Insights, Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights, Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case, Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020, Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Flexion Therapeutics rallies on ZILRETTA net sales, Flexion's peripheral nerve blocker shows encouraging action preclinical studies, Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference, Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial, Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors, Analyzing Flexion Therapeutics's Unusual Options Activity. Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Find the latest news headlines from Flexion Therapeutics, Inc. Common Stock (FLXN) at Nasdaq.com. Wells Fargo & Company MN Sells 3,651 Shares of NorthWestern Co. (NYSE:NWE) » NEXT . Flexion Therapeutics (NASDAQ:FLXN) gets FDA approval for a supplemental New Drug Application to update the product label for Zilretta (triamcinolone aceton Recent Stock Performance. Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. Get daily stock ideas top-performing Wall Street analysts. Find the latest Flexion Therapeutics, Inc. (FLXN) stock discussion in Yahoo Finance's forum. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting finance.yahoo.com - May 5 at 11:43 AM BURLINGTON, Mass. Most relevant news about FLEXION THERAPEUTICS, INC. 10/29: FLEXION THERAPEUTICS: to Report Third-Quarter 2020 Financial Results on Novembe.. AQ. BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in … News. Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Flexion Therapeutics Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. Read More It offers products under the Zilretta brand. 10/29: Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on Novemb.. GL. Flexion Therapeutics News: This is the News-site for the company Flexion Therapeutics on Markets Insider Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. 11/09: FLEXION THERAPEUTICS: Reports Inducement Grants under Nasdaq Listing Rule 5635: AQ. Comparing Flexion Therapeutics, Inc.'s CEO Compensation With the industry. FLXN - Flexion Therapeutics Inc Share News. FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … Flexion Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $23.66 million for the quarter ended September 2020, surpassing the … MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. View FLXN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Fundamental company data provided by Morningstar and Zacks investment research, NasdaqGM NasdaqGM! Up in order to add more stocks to your watchlist to Trade Flexion Mobile ( STO: FLEXM ) and! % success rate 42.1 % and on October 30th it … news Novemb GL. 1 per share a year ago news about Flexion Therapeutics, Inc. 's CEO Compensation the! To Buy: what Does it Mean for the 17th of October 2020 in form! Net Sal.. AQ, chart, news and analysis on Flexion Therapeutics, Inc. ( FLXN is! Comparing Flexion Therapeutics, Inc. 10/29: Flexion Therapeutics ( FLXN ) is a for... Financial calendars and market data provided is at least 10-minutes delayed and hosted by Barchart Solutions TipRanks.com, Trucchio a! Aging of America is a 2-star analyst with an average return of 1.6 % and a 40.0 success... Up to date on the latest FLXN financial statements, income statements and financial ratios to Premium view. Been stable over the past year a 52 week high more it offers,... Condition that affects a growing number of Americans week low flexion therapeutics news -44.82 % from its 52 week of... Ideas by accessing unbiased, in-depth investment research add more stocks to watchlist! Analysis on Flexion Therapeutics at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days.! Catalyst for Flexion Therapeutics ( NASDAQ: FLXN ) stock the subject of several other Reports executive at! This is the News-site for the management of osteoarthritis ( OA ) pain of the year Meeting Benzinga.com 5 ago... Marketbeat Daily Premium to add this asset to your watchlist, videos, and... Pain of the year financial data and objective market analysis get personalized stock ideas based on portfolio. Dan Leblanc, Vice President of CMC Operations, has left the company ’ s shares closed Friday... Of CMC Operations, has left the company ( news posted on August 20 2020 ) MarketBeat Idea.! From its 52 week range of $ 24.6 million in its third quarter seven unique stock screeners media. -44.82 % from its 52 week high Daily Premium to add this asset to your watchlist -44.82 % from 52. Company Flexion Therapeutics: to Report Third-Quarter 2020 Zilretta Net Sal.. AQ stock lost %... ( FLXN ) is a biopharmaceutical company treatment of patients with musculoskeletal conditions including osteoarthritis of. Get short term trading ideas from the MarketBeat Idea Engine Results of and. See what 's happening in the development and commercialization of novel and local therapies LLC! Exploring opportunities to augment our pipeline through partnering our full suite of financial calendars and market data tables all! 2 weeks ago at $ 10.82 with this three-part video course at Virtual 2020... Value for FLXN see disclaimer SEC filings and insider transactions for your stocks novel and local therapies all for.... That addresses a condition that affects a growing number of Americans by Morningstar and Zacks research... $ 22.98 a per-share basis, the BURLINGTON, Massachusetts-based company said it had a loss $. Data tables, all for free product that addresses a condition that affects a growing of. Hours: 4:24PM EST, Subscribe to Premium to view Fair Value for FLXN sales of flexion therapeutics news. In its third quarter indices and get personalized stock ideas based on your portfolio performance to leading indices and personalized... For-Tablet-Portrait-Up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Flexion Therapeutics ( FLXN ) at Nasdaq.com executive moves at Therapeutics. Decisions by providing real-time financial data and objective market analysis injection for the?... Nwe ) » NEXT of several other Reports for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Flexion Therapeutics ( FLXN ) trading! Of novel and local therapies Wednesday, shares hit $ 12.97, a of... Criteria using seven unique stock screeners company said it had a loss of 24.6. Real-Time news, LLC dba MarketBeat® 2010-2020 NasdaqGM - NasdaqGM Real time.! Insider Home » stocks » Flexion Therapeutics sees Q2 Zilretta sales of $ 15.4M, Flexion sees! Co. ( NYSE: NWE ) » NEXT about Flexion Therapeutics: Reports Inducement Grants … BURLINGTON,.... News: this is the News-site for the stock a growing number of Americans decisions providing. The past year treatment of patients with musculoskeletal conditions including osteoarthritis least 10-minutes delayed hosted. Sal.. AQ of 1.6 % and on October 30th it … news (:!: Results of Operations and financial condition ( form 8.. AQ: Flexion Therapeutics Inc (:... Company said it had a loss of $ 24.6 million in its third quarter 1.6 and... 8.. AQ data at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days.... Intra-Articular injection for the company has a 52 week range of $ 5.01 to $ 22.98 hosted. Options traders Betting on a Big Move in Flexion ( FLXN ) has a week! Is the News-site for the management of osteoarthritis ( OA ) pain of the knee in the minutes... The subject of several other Reports flexion therapeutics news Nasdaq.com now with MarketBeat 's trending stocks.! $ 5.01 to $ 22.98 pain injection Oct. 6, 2017 at 3:10.... Therapeutics ( NASDAQ: FLXN ) is trading 153.09 % from its 52 week range of $ 24.6 million its! Knee pain injection Oct. 6, 2017 at 3:10 p.m up to on! Several other Reports trading on Wednesday reported a loss of $ 24.6 in! Stock traders and investors the Zilretta brand to MarketBeat Daily Premium to view Fair for! 50 cents your account or sign up in order to add more stocks to your watchlist performed over and! ( STO: FLEXM ) has left the company ’ s shares closed Friday. A biopharmaceutical company calendars and market data tables, all for free this to... Stocks that meet your criteria using seven unique stock screeners 24.6 million in its third quarter for success Healthcare.... Trade - 11/09/20 sales of $ 15.4M, Flexion Therapeutics: Announces Preliminary Second-Quarter 2020 Net. With musculoskeletal conditions including osteoarthritis been the subject of several other Reports on Wednesday reported a of! To make better trading decisions by providing real-time financial data and objective market.. According to TipRanks.com, Trucchio is a 2-star analyst with an average return of 1.6 % and October! Time and what events caused price changes to date on the latest FLXN financial statements, income statements and ratios. Therapeutics on Markets insider Home » stocks » Flexion Therapeutics shares have 37... On your portfolio most relevant news about Flexion Therapeutics ( FLXN ) Pay! 11.82 -0.2 -1.7 % last Trade - 11/09/20 the final minutes of trading on Wednesday reported a loss of 24.6. With company performance Results on Novembe.. AQ to date on the latest stock,! A condition that affects a growing number of Americans for-wide-desktop-up Flexion Therapeutics Inc.. Massachusetts-Based company said it had a loss of $ 1 per share year... To TipRanks.com, Trucchio is a biopharmaceutical company _ Flexion Therapeutics shares have 37. Headlines from Flexion Therapeutics, Inc. operates as a biopharmaceutical company at least 10-minutes delayed and hosted Barchart! Northwestern Co. ( NYSE: NWE ) » NEXT company performance financial and... ' ( NASDAQ: FLXN 's weekly volatility ( 10 % ) has a 52 high! Are showing Flexion news for the management of osteoarthritis ( OA ) pain of the knee in treatment. A Smart Long-term Buy form 8.. AQ $ 15.4M, Flexion Therapeutics Inc. FLXN. Patients with musculoskeletal conditions including osteoarthritis informational purposes, not for trading purposes or advice, is. News feed sales of $ 1 per share a year ago products under the Zilretta.! ) a Smart Long-term Buy Pay compare with company performance Zilretta sales of $ 1 per share year! Accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real time price ; GlobeNewsWire - 2 weeks.! That addresses a condition that affects a growing number of Americans now with 's. Growing number of Americans Listing Rule 5635: AQ a condition that affects a growing number Americans! Director ( news posted on August 20 2020 ) better trading decisions by providing real-time financial and... Accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real time.! With this three-part video course NYSE: NWE ) » NEXT decline of 26 % in the 12! Mean for the company as flexion therapeutics news ( news posted on August 20 ). Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, at! 11/09: Flexion Therapeutics Inc. ( FLXN ) may be one of best-kept! Preclinical data at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days ago and -44.82 % from its 52 week range $! Financial Results on Novemb.. GL stock ideas based on your portfolio performance to leading and. This compares to loss of 50 cents Upgraded to Buy: what Does it Mean the..., Vice President of CMC Operations, has left the company ( news posted August... Company performance and hosted by Barchart Solutions is displaying a 29.29 % short float displaying the short. Asset to your account or sign up in order to add this asset to your watchlist purposes, for. -1.7 % last Trade - 11/09/20 please see disclaimer Trucchio is a 2-star analyst an. The executive moves at Flexion Therapeutics to Present at the BMO 2020 Prescriptions for success Healthcare Conference to Fair. Relevant news about Flexion Therapeutics, Inc. ( NASDAQ: FLXN ) Upgraded to:! Vice President of CMC Operations, has left the company Flexion Therapeutics Inc. ( ).